Investors Are Listening As Immutep Eyes Revolutionary Cancer Treatments, page-18

You are quite right @coco907. 6 months is a short call for budget but i was just trying to say cash level covering till 2021 does not necessarily mean a CR will not happen before then. A CR will have to happen, as you also say, withing 6 months of end 2021 ... but hopefully we will know of the indications of where the trials are heading by end 2020. I will not have a problem with a CR even say end Q1/21 if we have data to justify continuing to next phases ... I for myself anticipate it will be the case.

On that, I sense there is some misunderstanding that if data is good then we can "skip to commercialization" ... so to speak! No, if data is good then we can fast track but still need capital, unless our CFO will have done his homework to come up with a more suitable funding in that case.

While we are at it, there ARE A LOT of "bio" stocks on ASX which, due to lifestyle management, burn cash at astronomical rate and often they do CR withing a month or so of running out !!! I think we are not one of them.